ArticleBioinformation2025
Adverse drug reaction (ADR) monitoring of antihypertensive drugs in a tertiary care setting: A prospective observational study.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Cohort Study on Incidence and Factors Associated With Adverse Drug Reactions of Enalapril in Lusaka, Zambia.Pharmacology research & perspectives · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension requires long-term therapy. However, antihypertensive drugs may cause adverse drug reactions (ADRs) affecting compliance and quality of life. This 12-month prospective observational study included 500 patients receiving at least one antihypertensive medication. A total of 95 ADRs (17.6%) were identified, most commonly due to calcium channel blockers and ACE inhibitors, with pedal edema, dry cough and dizziness being the frequent events. ADRs were significantly higher in patients on polypharmacy (p = 0.004) and most were classified as moderate and probable. Active pharmacovigilance is essential to improve safety and optimize hypertension management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.